BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20045804)

  • 1. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
    Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
    Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.
    Vieira Neto L; Chimelli L; Pereira PJ; Gasparetto EL; Bines J; Wildemberg LE; Gadelha MR
    Endocr Pract; 2013; 19(6):e145-9. PubMed ID: 23807517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
    Ersen A; Syro LV; Penagos L; Uribe H; Scheithauer BW; Ortiz LD; Rotondo F; Horvath E; Kovacs K
    Can J Neurol Sci; 2012 Sep; 39(5):683-5. PubMed ID: 23066557
    [No Abstract]   [Full Text] [Related]  

  • 16. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
    Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
    Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.